Spotlight On... inVentiv opens new Phase I clinic; Pfizer taps Adaptive for immunotherapy R&D; and much more...

CRO inVentiv Health is expanding its early-stage research capabilities, opening a new Phase I clinic in Florida. The facility, sited at the University of Miami Life Science and Technology Park, has room for 44 beds, complementing inVentiv's existing Phase I-IV services around the U.S., the company said. More

> Pfizer ($PFE) signed a deal with Adaptive Biotechnologies to use the company's genomic sequencing technology in its efforts to develop immuno-oncology therapies. News

> The Indian CRO market has plenty of room to grow, according to the departing CEO of Biocon's Syngene. Story